Commercial Insight: Osteoporosis

Market players maximize revenue growth before the next challenging phase

Product Code DAT05902
Publication Date July 2010
Publisher Datamonitor
Product Type Report
Pages 207
ISBN Number not applicable
Change currency
PDF £9,615.00 €11,579 $15,204 BUY >
PRINT £9,675 €11,651 $15,299 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Commercial Insight: Osteoporosis

Market players maximize revenue growth before the next challenging phase

Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005-09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.

Scope

  • Analysis of global osteoporosis prescriptions from 2005-09, split by geographical region (including emerging markets), drug class, and brand.
  • Discussion of key commercial opportunities and threats in the US, Japan, and five major European markets.
  • In depth profiles of 13 key osteoporosis brands and pipeline agents with SWOT analyses and country-specific sales forecasts to 2019.
  • Detailed analysis of key developer trends, strategies and portfolios including a case study of Novartis's Aclasta (zoledronic acid).

Highlights

The rest of world, outside of the seven major markets, achieved osteoporosis-specific sales of $2.4 billion in 2009 with an impressive CAGR of 8.7% from 2005. Brazil, Russia, India and China were the fastest growing nations, driving a combined 2005-09 CAGR of 17%.

The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. However, the increase in cost pressure resulting from generic penetration poses a major barrier to entry.

Leading market players continue to pursue their direct-to-consumer advertising campaigns, sponsoring events to raise awareness of the disorder and of respective treatments. Innovative strategies to increase brand loyalty and confidence, such as risk-sharing schemes, have also been implemented by Novartis and Sanofi-Aventis.

Reasons to Purchase

  • Understand historical (2005-09) and future (2010-19) osteoporosis drug market dynamics and competitive environment.
  • Gain insight into the main opportunities and threats specific to the osteoporosis market.
  • Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2019 in the US, Japan, France, Germany, Italy, Spain, and the UK.

Contents

  • Overview
    • Catalyst
    • Summary
  • Executive Summary
    • Strategic scoping and focus
    • Datamonitor insight into the osteoporosis market
    • Related reports
    • Upcoming related reports
    • Table of Contents
  • Market Definition
    • Market definition for this report
  • Market Overview
    • Seven major markets
    • Current and future market overview
    • despite a recent setback the osteoporosis market will resume growth
    • Regional dynamics: the US is set to remain the largest major market but Japan and the EU are also growing
    • Anatomical Therapeutic Chemical (ATC) class dynamics
    • Brand splits
    • Opportunities and threats
    • Opportunity one: anabolic drugs still needed
    • Opportunity two: the male osteoporosis market remains underdeveloped
    • Opportunity three: aging population increases osteoporosis population
    • Opportunity four: raising awareness remains critical to expand the patient population
    • Opportunity five: as patent expiries near there will be reduced marketing competition
    • Threat one: the osteoporosis market is becoming highly genericized, increasing cost competitiveness
  • US
    • Current and future market assessment
    • despite new drug launches US market growth will slow down
    • Bisphosphonates will remain the largest osteoporosis drug class in the US
    • Brand dynamics
    • Opportunities and threats
    • Opportunity one: the US healthcare reform increases the treatable patient population
    • Opportunity two: the US health reform aims to close the donut hole
    • Opportunity three: risk-sharing schemes increase brand loyalty
    • Threat one: speed to market in the US is greatly reduced as FDA increases scrutiny
    • Threat two: FDA tightens marketing controls in the US
  • Japan
    • Current and future market assessment
    • Japanese market set to grow after new drug launches
    • Opportunities and threats
    • Opportunity one: launch of new drugs
    • Opportunity two: training of physicians
    • Opportunity three: partnerships with Japanese Pharma companies is beneficial
    • Threat 1: Cost cutting policies
  • Five major EU markets
    • Current and future market assessment
    • Italy and Spain are the fastest growing osteoporosis markets in the five major EU region
    • Anabolic drugs and new drug classes drive market growth
    • Opportunities and threats
    • Opportunity one: osteoporosis remains a priority in the European Union
    • Threat one: in Germany, reimbursement of treatment and diagnostic scans remains limited
    • Threat two: German government increases the pressure to manage the cost of healthcare with NICE equivalent
    • Threat three: NICE continues to restrict drug access in the UK in favor of alendronate
    • France
      • Current and future market assessment
    • Germany
      • Current and future market assessment
    • Italy
      • Current and future market assessment
    • Spain
      • Current and future market assessment
    • UK
      • Current and future market assessment
  • Rest of the world snapshot
    • Current market assessment
    • The global osteoporosis market shrank in 2009
    • The rest of the world accounted for 26% of the global osteoporosis market in 2009
    • The rest of the world outstrips the seven major markets in terms of volume
    • BRIC and Canada were the only markets to display growth between 2008 and 2009
    • Bisphosphonates and calcium dominate the rest of the world osteoporosis market but anabolic drugs are the fastest growing
  • Brand Dynamics
    • Overview of competitive landscape
    • Patient acquisition process
    • Introduction
    • Patient care path
    • Points of influence in the patient care path
    • Trigger point one: osteoporosis prevention
    • Trigger point two: disease severity influences osteoporosis treatment
    • Trigger point three: compliance issues and fractures
    • Drivers of drug choice
    • US formulary tier status for leading brands
    • EU osteoporosis reimbursement policies
    • Trends in marketing strategies
    • Marketing strategy for leading brands
    • Sponsorship/disease awareness campaigns
    • Direct-to-consumer advertising
    • Bisphosphonates: Fosamax/Fosamax plus D (alendronate; Merck & Co)
    • Drug profile
    • Alendronate generics still available in Europe despite 2006 European Patent Office ruling
    • Product positioning
    • Fosamax is positioned as the market gold standard
    • SWOT analysis
    • Brand forecast to 2019
    • Fosamax plus D fails to maintain market share upon alendronate generic penetration in the US
    • Bisphosphonates: Actonel/Actonel with Calcium (risedronic acid; Sanofi-Aventis/Warner Chilcott)
    • Drug profile
    • Product positioning
    • Actonel is commonly positioned as a first-line alternative to Fosamax
    • SWOT analysis
    • Brand forecast to 2019
    • Bisphosphonates: Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline)
    • Drug profile
    • Product positioning
    • Bonviva caters for two different types of patients
    • Bonviva sales remain lower than other bisphosphonates due to lack of non-vertebral fracture protection data
    • SWOT analysis
    • Brand forecast to 2019
    • Bisphosphonates: Aclasta (zoledronic acid; Novartis)
    • Drug profile
    • Product positioning
    • First yearly osteoporosis therapy tackles compliance issues
    • SWOT analysis
    • Brand forecast to 2019
    • Bisphosphonates: Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical)
    • Drug profile
    • Product positioning
    • SWOT analysis
    • Brand forecast to 2019
    • Selective estrogen receptor modulators: Evista (raloxifene; Eli Lilly)
    • Drug profile
    • Product positioning
    • Evista is positioned as a treatment for mild osteoporosis and osteopenia
    • SWOT analysis
    • Brand forecast to 2019
    • Selective estrogen receptor modulators: Conbriza/Viviant (bazedoxifene; Pfizer)
    • Drug overview
    • Product positioning
    • Should Conbriza launch it will be the second SERM to reach the osteoporosis market
    • Conbriza is likely to be positioned as a follow-on therapy to Aprela
    • SWOT analysis
    • Brand forecast to 2019
    • Selective estrogen receptor modulators: Fablyn (lasofoxifene; Pfizer/Ligand)
    • Drug overview
    • Product positioning
    • Physicians are unlikely to prescribe Fablyn over Evista
    • SWOT analysis
    • Brand forecast to 2019
    • Parathyroid hormones: Forteo (teriparatide; Eli Lilly)
    • Drug profile
    • Product positioning
    • Forteo remains positioned to treat severe osteoporosis patients due to it high cost
    • SWOT analysis
    • Brand forecast to 2019
    • Parathyroid hormones: Preotact (full-length parathyroid hormone PTH 1-84; NPS/Nycomed)
    • Drug profile
    • Product positioning
    • SWOT analysis
    • Brand forecast to 2019
    • Dual acting bone agents: Protelos (strontium ranelate; Servier)
    • Drug profile
    • Product positioning
    • Protelos uniquely combines anabolic and antiresorptive action
    • SWOT analysis
    • Brand forecast to 2019
    • Calcitonins: Miacalcic (calcitonin-salmon; Novartis)
    • Drug profile
    • Product positioning
    • SWOT analysis
    • Brand forecast to 2019
    • Calcitonins: Fortical (calcitonin-salmon; Unigene)
    • Drug profile
    • Product positioning
    • SWOT analysis
    • Brand forecast to 2019
    • Pipeline drugs: Prolia (denosumab; Amgen/GlaxoSmithKline)
    • Drug profile
    • Development overview
    • Product positioning
    • SWOT analysis
    • Drug forecast to 2019
    • Pipeline drugs: Eldecalcitol (ED-71; Chugai/Taisho)
    • Product positioning
    • SWOT analysis
    • Drug forecast to 2019
  • Key Developers
    • Strategic overview
    • Trends in corporate strategy
    • Intermittent dosing
    • Differentiation remains key to success
    • Innovative lifecycle management strategies
    • Recent strategic partnerships/deals
    • Offsetting of lack of research with deals
    • Merck & Co
    • Corporate strategy
    • Osteoporosis portfolio assessment
    • Eli Lilly
    • Corporate strategy
    • Osteoporosis portfolio assessment
    • Portfolio assessment of other leading companies
    • Novartis: continued interest in the market is reflected in the pipeline activity
    • GlaxoSmithKline: deal with Amgen allows GlaxoSmithKline to keep market share
    • Pfizer: Wyeth acquisition allows Pfizer to finally enter this market
  • Case Studies
    • Aclasta: the market leader that never was
    • Once yearly addresses compliance, but mode of administration limits use
    • Access to Aclasta remains problematic in many major markets
    • Overall the cost for Aclasta does not exceed other bisphosphonate therapies
    • Reimbursement policies can affect the frequency with which the drug is used
    • Patient and physician education
  • Bibliography
    • Journal papers
    • Websites
    • Datamonitor reports
    • Conferences attended
  • Appendix A
  • Market Assumptions
    • New product launches and expiries
    • Data definitions, limitations and assumptions
    • Standard units
    • Country group definitions
    • Rest of European Union
    • Middle East and North Africa (MENA)
    • Rest of World
    • Derivation of sales forecasts and pricing trends
    • Indication-specific sales calculations
    • Caveats to using Prescribing insight
    • Forecast methodology
  • Appendix B
    • Contributing experts
    • Conferences attended
    • Report methodology
    • about Datamonitor
    • about Datamonitor Healthcare
    • about the Genitourinary analysis team
    • Disclaimer
  • List of Tables
    • Table 1: Summary of therapeutic classes in osteoporosis by Anatomical Therapeutic Chemical (ATC) code, 2009
    • Table 2: Summary of the ICD-10 codes used to derive osteoporosis-specific sales from each brand
    • Table 3: Regional osteoporosis market value sales ($m) in the seven major markets, 2005-2019
    • Table 4: Anatomical Therapeutic Chemical (ATC) class sales dynamics ($m) in osteoporosis across the seven major markets, 2005-2019
    • Table 5: Osteoporosis brand sales ($m) dynamics across the seven major markets, 2009-2019
    • Table 6: Key events impacting the osteoporosis market, by region, 2010-2019
    • Table 7: Osteoporosis global market opportunities and threats, 2010-2019
    • Table 8: Summary of key osteoporosis drug patent expiries in the seven major markets, 2010-2020
    • Table 9: Prices of key osteoporosis drugs in the US and the five major EU markets, 2009
    • Table 10: Osteoporosis sales ($m) dynamics in the US by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 11: Osteoporosis brand sales ($m) dynamics in the US, 2009-2019
    • Table 12: Osteoporosis market opportunities and threats in the US, 2010-2019
    • Table 13: Uninsured osteoporosis population in the US aged 50-64 years, 2010
    • Table 14: Medicare payments, 2009
    • Table 15: Price per year ($) of key osteoporosis brands in the US, 2009
    • Table 16: Osteoporosis sales ($m) dynamics in Japan by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 17: Osteoporosis brand sales ($m) dynamics in Japan, 2009-2019
    • Table 18: Osteoporosis market opportunities and threats in Japan, 2010-2019
    • Table 19: Osteoporosis sales ($m) dynamics in the five major EU markets, 2005-2019
    • Table 20: Osteoporosis sales ($m) dynamics in the five major EU markets by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 21: Osteoporosis brand sales ($m) dynamics in the five major EU markets, 2009-2019
    • Table 22: Osteoporosis market opportunities and threats in the five major EU markets, 2010-2019
    • Table 23: Implementation of EU recommendations in the five major EU markets, 2008
    • Table 24: Osteoporosis sales ($m) dynamics in France by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 25: Osteoporosis sales forecasts in France ($m), 2009-2019
    • Table 26: Osteoporosis sales ($m) dynamics in Germany by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 27: Osteoporosis sales forecasts in Germany ($m), 2009-2019
    • Table 28: Osteoporosis sales ($m) dynamics in Italy by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 29: Osteoporosis sales forecasts in Italy ($m), 2009-2019
    • Table 30: Osteoporosis sales ($m) dynamics in Spain by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 31: Osteoporosis sales forecasts in Spain ($m), 2009-2019
    • Table 32: Osteoporosis sales ($m) dynamics in the UK by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Table 33: Osteoporosis sales forecasts in the UK ($m), 2009-2019
    • Table 34: Global sales ($m) dynamics of the osteoporosis market, 2005-09
    • Table 35: Regional split of the global osteoporosis market sales, 2005-09
    • Table 36: Rest of the world osteoporosis sales by Anatomical Therapeutic Chemical (ATC) class, 2005-09
    • Table 37: Leading branded drug sales for osteoporosis in the seven major markets ($m), 2009-2019
    • Table 38: Key products in late-stage R&D pipeline for osteoporosis, 2010
    • Table 39: Results from the Timeless Woman Study, 2008
    • Table 40: Representative formulary tier status in the US for leading brands in osteoporosis, 2010
    • Table 41: EU osteoporosis treatment reimbursement policies, 2008
    • Table 42: Marketing strategies employed by the companies behind the top three pain market brands, 2010
    • Table 43: Fosamax (alendronate; Merck & Co.): key facts, 2010
    • Table 44: Impacting factors on the revenues of the Fosamax brand franchise (alendronate; Merck & Co), 2010-2019
    • Table 45: Actonel (risedronic acid; Sanofi-Aventis/Warner Chilcott): key facts, 2010
    • Table 46: Impacting factors on the revenues of the Actonel brand franchise, 2010-2019
    • Table 47: Bonviva (ibandronic acid; Roche/GlaxoSmithKline): key facts, 2010
    • Table 48: Impacting factors on the revenues of the Bonviva brand franchise, 2010-2019
    • Table 49: Aclasta (zoledronic acid; Novartis): key facts, 2010
    • Table 50: Impacting factors on the revenues of Aclasta, 2010-2019
    • Table 51: Bonoteo (minodronic acid; Astellas/Ono Pharmaceutical): key facts, 2010
    • Table 52: Evista: key facts, 2010
    • Table 53: Impacting factors on the revenues of Evista, 2010-2019
    • Table 54: Conbriza (bazedoxifene; Pfizer): key facts, 2010
    • Table 55: Impacting factors on the revenues of Conbriza, 2010-2019
    • Table 56: Fablyn (lasofoxifene; Pfizer/Ligand): key facts, 2010
    • Table 57: Impacting factors on the revenues of Fablyn (lasofoxifene; Pfizer/Ligand), 2010-2019
    • Table 58: Forteo (teriparatide; Eli Lilly): key facts, 2010
    • Table 59: Impacting factors on the revenues of Forteo (teriparatide; Eli Lilly), 2010-2019
    • Table 60: Preotact (full-length parathyroid hormone PTH 1-84; NPS/Nycomed): key facts, 2010
    • Table 61: Impacting factors on the revenues of Preotact, 2010-2019
    • Table 62: Protelos (strontium ranelate; Servier): key facts, 2010
    • Table 63: Impacting factors on the revenues of Protelos, 2010-2019
    • Table 64: Miacalcic (calcitonin-salmon; Novartis): key facts, 2010
    • Table 65: Impacting factors on the revenues of Miacalcic (calcitonin-salmon; Novartis), 2010-2019
    • Table 66: Fortical (calcitonin-salmon; Unigene): key facts, 2009
    • Table 67: Impacting factors on the revenues of Fortical (calcitonin-salmon; Unigene, 2009-2018
    • Table 68: Prolia (denosumab; Amgen/GlaxoSmithKline): key facts, 2010
    • Table 69: Summary of key Prolia (denosumab; Amgen/GlaxoSmithKline) studies, 2010
    • Table 70: Impacting factors on the revenues of Prolia (denosumab; Amgen/GlaxoSmithKline) in osteoporosis, 2010-2019
    • Table 71: Eldecalcitol (ED-71; Chugai/Taisho): key facts, 2010
    • Table 72: Summary of key clinical trials for eldecalcitol (ED-71; Chugai/Taisho), 2010
    • Table 73: Key strategic deals and events in the osteoporosis market, 2008-2010
    • Table 74: Merck & Co osteoporosis portfolio assessment, 2010
    • Table 75: Eli Lilly osteoporosis portfolio assessment, 2010
    • Table 76: Novartis's osteoporosis portfolio assessment, 2010
    • Table 77: GlaxoSmithKline's osteoporosis portfolio assessment, 2010
    • Table 78: Pfizer's osteoporosis portfolio assessment, 2010
    • Table 79: Key drivers and resistors to the use of Aclasta, 2010
    • Table 80: Prices per year ($) of key osteoporosis drugs in the US and the five major EU drugs, 2009
    • Table 81: Patent expiry dates for key marketed brands in osteoporosis in the US and Japan, 2010
    • Table 82: Patent expiry dates for key marketed brands in osteoporosis in the five major European market regions, 2010
    • Table 83: Estimated launch dates for key late-stage pipeline products and marketed brands in the seven major market regions, 2009-2018
  • List of Figures
    • Figure 1: Osteoporosis market sales ($m) across the seven major markets, 2005-2019
    • Figure 2: Osteoporosis market sales (IMS Standard Units) across the seven major markets, 2005-2019
    • Figure 3: Regional osteoporosis market value sales ($m) in the seven major markets, 2005-09
    • Figure 4: Regional osteoporosis market value sales ($m) in the seven major markets, 2009-2019
    • Figure 5: Anatomical Therapeutic Chemical (ATC) class sales dynamics ($m) in osteoporosis across the seven major markets, 2005-09
    • Figure 6: Anatomical Therapeutic Chemical (ATC) class sales dynamics ($m) in osteoporosis across the seven major markets, 2009-2019
    • Figure 7: Osteoporosis antiresorptive and anabolic drugs sales ($) dynamics in the seven major markets, 2005-2019
    • Figure 8: Antiresorptive and anabolic pipelines for osteoporosis, 2005 and 2010
    • Figure 9: Lifetime risk of hip fracture at 50 years in men versus women by country, 2002
    • Figure 10: Change in the population over 50 years of age across the seven major markets, 2010-2020
    • Figure 11: Increase of male and female osteoporosis over the age of 50 years' patient potential by severity in the seven major markets, 2010-2020
    • Figure 12: Women perception of health priorities in the five major EU markets, 2000
    • Figure 13: Comparison of screening for different diseases in the five major EU markets, 2000
    • Figure 14: Osteoporosis sales across the seven major markets, 2005-2019
    • Figure 15: Osteoporosis sales ($m) dynamics in the US, 2005-2019
    • Figure 16: Osteoporosis sales ($m) dynamics in Japan, 2005-2019
    • Figure 17: Japan osteoporosis market ($m), 2009-2019
    • Figure 18: Osteoporosis sales ($m) dynamics in the five major EU markets, 2005-09
    • Figure 19: Osteoporosis sales ($m) dynamics in the five major EU markets, 2009-2019
    • Figure 20: Osteoporosis sales ($m) dynamics in the five major EU markets by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Figure 21: The burden of osteoporosis (DALYs) compared to cancers, 2006
    • Figure 22: Osteoporosis sales ($m) dynamics in France, 2005-2019
    • Figure 23: Osteoporosis sales ($m) dynamics in Germany, 2005-2019
    • Figure 24: Osteoporosis sales ($m) dynamics in Italy by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Figure 25: Osteoporosis sales ($m) dynamics in Spain by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Figure 26: Osteoporosis sales ($m) dynamics in the UK by Anatomical Therapeutic Chemical (ATC) class, 2005-2019
    • Figure 27: Global osteoporosis market sales ($m), 2005-09
    • Figure 28: Global osteoporosis market sales ($m) dynamics, 2005-09
    • Figure 29: Global osteoporosis market volume (IMS standard units sold) and value ($) sales, by region, 2009
    • Figure 30: Rest of the world osteoporosis market sales value ($m), 2005-09
    • Figure 31: Rest of the world osteoporosis market regional dynamics, 2005-09
    • Figure 32: Rest of the world osteoporosis sales by Anatomical Therapeutic Chemical (ATC) class, 2005-09
    • Figure 33: Rest of the world osteoporosis sales dynamics by Anatomical Therapeutic Chemical (ATC) class, 2005-09
    • Figure 34: Osteoporosis patient care path in the seven major markets, 2010
    • Figure 35: Key drivers of drug choice in osteoporosis across the seven major markets
    • Figure 36: Assessment of formulary status in osteoporosis in the US, 2010
    • Figure 37: Amgen's 'Know My Bones' osteoporosis patient information website , 2010
    • Figure 38: GlaxoSmithKline's and Roche's celebrity spokesperson strategy for marketing Bonviva in the US
    • Figure 39: Actonel (risedronate; Sanofi-Aventis/Warner Chilcott) web page, 2010
    • Figure 40: Fosamax brand franchise (alendronate; Merck & Co): SWOT analysis, 2010
    • Figure 41: Fosamax brand franchise (alendronate; Merck & Co) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 42: Fosamax brand franchise (alendronate; Merck & Co) sales ($m) performance for osteoporosis in the seven major markets, 2005-2019
    • Figure 43: Actonel brand franchise (risedronic acid; Sanofi-Aventis/Warner Chilcott): SWOT analysis, 2010
    • Figure 44: Actonel brand franchise (risedronic acid; Sanofi-Aventis/Warner Chilcott) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 45: Actonel brand franchise (risedronic acid; Sanofi-Aventis/Warner Chilcott) sales performance for osteoporosis in the seven major markets, 2005-2019
    • Figure 46: Bonviva brand franchise (ibandronate; Roche/GlaxoSmithKline): SWOT analysis, 2010
    • Figure 47: Bonviva brand franchise (ibandronate; Roche/GlaxoSmithKline) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 48: Bonviva brand franchise (ibandronate; Roche/GlaxoSmithKline) sales performance for osteoporosis in the seven major markets, 2005-2019
    • Figure 49: Aclasta: SWOT analysis, 2010
    • Figure 50: Aclasta (zoledronic acid; Novartis) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 51: Bonoteo (minodronic acid; Astellas/Ono Pharmaceutical): SWOT analysis, 2010
    • Figure 52: Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 53: Evista: SWOT analysis, 2010
    • Figure 54: Evista (raloxifene; Eli Lilly) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 55: Conbriza: SWOT analysis, 2010
    • Figure 56: Conbriza (bazedoxifene; Pfizer) osteoporosis sales ($m) forecast across the seven major markets, 2011-19
    • Figure 57: Fablyn (lasofoxifene; Pfizer/Ligand): SWOT analysis, 2010
    • Figure 58: Fablyn (lasofoxifene; Pfizer) osteoporosis sales ($m) forecast across the seven major markets, 2011-19
    • Figure 59: Forteo (teriparatide, Eli Lilly): SWOT analysis, 2010
    • Figure 60: Forteo (teriparatide; Eli Lilly) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 61: Preotact (full-length parathyroid hormone PTH 1-84; NPS/Nycomed): SWOT analysis, 2010
    • Figure 62: Preotact (PTH 1-84; Nycomed) osteoporosis sales ($m) forecast across the seven major markets, 2007-2019
    • Figure 63: Protelos (strontium ranelate, Servier): SWOT analysis, 2010
    • Figure 64: Protelos (strontium renalate; Servier) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 65: Miacalcic (calcitonin-salmon; Novartis): SWOT analysis, 2010
    • Figure 66: Miacalcic (calcitonin salmon; Novartis) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 67: Fortical: SWOT analysis, 2009
    • Figure 68: Fortical (calcitonin salmon; Unigene) osteoporosis sales ($m) forecast across the seven major markets, 2005-2019
    • Figure 69: Prolia (denosumab; Amgen): SWOT analysis, 2010
    • Figure 70: Prolia (denosumab; Amgen/GlaxoSmithKline) osteoporosis sales ($m) forecast across the seven major markets, 2010-2019
    • Figure 71: Eldecalcitol (ED-71, Chugai/Taisho): SWOT analysis, 2010
    • Figure 72: Eldecalcitol (ED-71; Chugai/Taisho) osteoporosis sales ($m) forecast across the seven major markets, 2010-2019